文献速递妇科生殖医学

子宫内膜异位症疼痛临床应答与健康相关生活质量及工作效率改善相关:两项III期临床试验分析

Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
PubMed 文献 · Am J Obstet Gynecol · 2019-11-22

该事后分析基于Elaris子宫内膜异位症-I和-II两项III期随机安慰剂对照试验,纳入痛经或非经期盆腔痛临床应答者,评估其第3个月时健康相关生活质量与工作效率变化。结果显示,临床应答者在子宫内膜异位症健康量表-30所有领域均有临床意义改善,痛经应答者工作效率损失显著少于无应答者。

要点

  • 痛经或非经期盆腔痛临床应答者第3个月子宫内膜异位症健康量表-30所有领域均获临床意义改善。
  • 无临床应答者第3个月健康量表领域评分未达应答者阈值。
  • Elaris-I中痛经应答者就业相关工作时间损失5.9小时 vs 无应答者13.0小时(P<.0001)。

核心结论

  • 中重度子宫内膜异位症相关疼痛患者中,基于痛经和非经期盆腔痛的临床应答者,其健康相关生活质量和工作效率也获得显著且有临床意义的改善。

研究设计与样本

  • 事后分析,使用Elaris子宫内膜异位症-I(n=871)和Elaris子宫内膜异位症-II(n=815)两项III期随机安慰剂对照研究的数据。
  • 纳入标准包括过去10年内子宫内膜异位症手术诊断、绝经前、18-49岁、中重度子宫内膜异位症相关疼痛。
  • 临床应答定义为未增加镇痛药使用且在第3个月达到疼痛减轻评分阈值,阈值通过受试者工作特征曲线分析分别针对痛经和非经期盆腔痛确定。

主要发现

  • 痛经或非经期盆腔痛临床应答者在第3个月子宫内膜异位症健康量表-30所有领域均获有临床意义的改善。
  • 无痛经或非经期盆腔痛临床应答者第3个月健康量表领域评分未显示达到应答者标准的平均改善。
  • Elaris-I中痛经临床应答者第3个月就业相关工作时间损失总计5.9小时 vs 无应答者13.0小时(P<.0001)。
  • Elaris-II中痛经应答者第3个月就业相关工作时间损失总计4.1小时 vs 无应答者10.4小时(P<.001)。
  • 按非经期盆腔痛应答状态分析获得相似结果。

关键数值与推荐

  • 疼痛每日自评采用0(无痛)至3(重度疼痛)量表,根据自报出血将每日疼痛归为痛经或非经期盆腔痛。
  • 临床应答定义为未增加镇痛药使用且在第3个月达到疼痛减轻评分阈值,阈值通过受试者工作特征曲线分析确定。
  • 健康相关生活质量采用子宫内膜异位症健康量表-30评估,工作效率采用健康相关工作效率问卷评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endometriosis-related pain symptoms have a negative impact on health-related quality of life and productivity. In fact, as endometriosis-related symptom severity and the number of symptoms experienced increases, health-related quality of life decreases. Dysmenorrhea and nonmenstrual pelvic pain are prominent symptoms experienced by women with endometriosis and were shown to have improved with the oral, nonpeptide gonadotropin-releasing hormone antagonist, elagolix. OBJECTIVE: The objective of this post hoc analysis was to address the question of if patients show a clinical response (in dysmenorrhea or nonmenstrual pelvic pain), do they also have improvements in health-related quality of life and in productivity? STUDY DESIGN: This post hoc analysis used data from the Elaris Endometriosis-I and Elaris Endometriosis-II phase III, randomized, placebo-controlled studies. A surgical diagnosis of endometriosis (in the past 10 years), premenopausal, aged 18-49 years, and moderate to severe endometriosis-associated pain were among the inclusion criteria for both trials. Women self-reported pain daily using a scale ranging from 0 (no pain) to 3 (severe pain); daily pain was assigned to either dysmenorrhea or nonmenstrual pelvic pain based on self-reported bleeding on that particular day. In addition, their self-reported endometriosis-associated pain must have been an average of moderate or severe during the month leading to baseline for inclusion in the trial program. Patients were characterized as achieving a clinical response for dysmenorrhea or nonmenstrual pelvic pain (ie, responder or nonresponder), which was defined as women who did not have an increase in analgesic use and who met the pain reduction score threshold at month 3. Pain reduction score thresholds were defined separately for dysmenorrhea and nonmenstrual pelvic pain in the trial using receiver-operating characteristics analysis. Health-related quality of life was assessed using the Endometriosis Health Profile-30; work productivity was assessed using the Health-Related Productivity Questionnaire. RESULTS: Women enrolled in Elaris Endometriosis-I (n = 871) and Elaris Endometriosis-II (n = 815) were included in this analysis. Patients with a clinical response during treatment to dysmenorrhea or nonmenstrual pelvic pain also experienced a meaningful improvement in all domains of the Endometriosis Health Profile-30 at month 3. Patients who did not show a dysmenorrhea or nonmenstrual pelvic pain clinical response at month 3 did not exhibit mean improvements in Endometriosis Health Profile-30 domain scores that indicate an Endometriosis Health Profile-30 responder. Productivity improved among dysmenorrhea clinical responders. In the Elaris Endometriosis-I study, clinical responders lost a total of 5.9 hours compared with a total of 13.0 hours for nonresponders of employment-related work at month 3 (P < .0001). Among women in the Elaris Endometriosis-II study, a total of 4.1 hours and 10.4 employment-related hours were lost at month 3 for dysmenorrhea responders vs nonresponders (P < .001). Similar results were obtained when analyzed by non-enstrual pelvic pain responder status. CONCLUSION: Women with moderate to severe endometriosis-related pain, who are clinical responders based on dysmenorrhea and nonmenstrual pelvic pain, also experience significant and clinically meaningful improvement in health-related quality of life and productivity as measured by the Endometriosis Health Profile-30 and Health-Related Productivity Questionnaire, respectively.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pokrzywinski RM, Soliman AM, Chen J, et al. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. Am J Obstet Gynecol. 2019. PMID: 31759891. doi:10.1016/j.ajog.2019.11.1255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。